Advanced Therapy Medicinal Products (ATMPs) are cutting-edge medicines based on cell, gene, or tissue engineering. The goal of ATMP 2030 is to ensure that Sweden will become a leader in the development and implementation of advanced therapies by 2030.
The focus areas of this initiative are:
National coordination and strengthening of the network
Increased capacity for the industrial development and manufacture of ATMPs
Effective processes for availability of cost-effective ATMPs within Swedish healthcare
Increase knowledge and secure future competence needs
Organization and financing models for sustainable continuation
This cross-functional collaboration between healthcare, industry, and the authorities is now entering its 2nd phase which aims to close urgent gaps in the Swedish ATMP ecosystem, including establishing hospital ATMP centers and a national infrastructure for commercial development.